November 25, 2024 4:38pm

Sector trades higher at the start of the shortened week awaiting Wednesday's Personal Consumption Expenditures (PCE) report

Although, trading volume is likely to be light this week due to the Thanksgiving holiday and close early on Friday

It’s about defining insight. Who speaks out while standing in-front, beside and behind investors – RMi

Never leave an investor uninformed!  

On point, short on words, long on facts and being judicious!

It’s hard to be right so often, it’s about defining insight. Who speaks out while standing in-front, beside and behind investors – RMi

 

RegMed Investors’ (RMi) pre-open: I hunger for more upside and turkey … https://www.regmedinvestors.com/articles/13711

 

Monday: The Dow closed UP +440.06 points or +0.99%, the S&P closed UP +18.03 points or +0.30% while the Nasdaq closed UP +51.18 points or +0.27%

  • Touched new records on Monday, kicking off the shortened trading week

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

  • For once, NONE

Monday’s advance/decline line at the open was positive with 31 incliners, 1 declined and 3 flats; ending with a positive close at the close of 28 incliner, 6 decliners and 1 flat

  • A wider sector rally than Friday

Metrics:  Monday, the IBB was up +1.95%, the XBI was up +1.39% while the VIX was down -0.46 points or -3.03% at 14.78

 

Ebb and flow of MY covered sector cell and gene therapy session daily “endings”: 

Q4/24 November – 9 negative and 8 positive closes       

  • October: 8 positive and 15 negative sessions

 

Monday’s Closing Down (6 of 6): -$ after Friday’s

  • Vericel VCEL -$3.49 after Friday’s +$2.40),
  • Blueprint Medicine (BPMC -$0.28 after Friday’s -$2.47),
  • Ultragenyx Pharmaceuticals (RARE -$0.12 after Friday’s +$1.22),
  • MiMedx (MDXG -$0.11 after Friday’s -$0.02),
  • Editas Medicine (EDIT -$0.06),
  • Regenxbio (RGNX -$0.01 after Friday’s +$0.41)

Flat (1):

  • Homology Medicine (FIXX)

Monday’s Closing Up (10 of 28):

  • Alnylam Pharmaceuticals (ALNY +$6.09 after Friday’s -$1.91),
  • Moderna (MRNA +$2.56 after Friday’s +$2.86),
  • CRISPR Therapeutics (CRSP +$2.52 after Friday’s +$1.59),
  • Beam Therapeutics (BEAM +$1.60 after Friday’s +$1.47),
  • Ionis Pharmaceuticals (IONS +$1.45),
  • Mesoblast (MESO +$0.92 after Friday’s -$0.17),
  • BioLife Solutions (BLFS +$0.76 after Friday’s +$0.62),
  • Intellia Therapeutics (NTLA +$0.49 after Friday’s +$0.50)
  • Solid Biosciences (SLDB +$0.45),
  • Verve Therapeutics (VERV +$0.44)

 

The BOTTOM LINE: more upside value flows into the sector share pricing …

I am increasingly worried about the possibility of a short-term 5-10% pullback, primarily due to elevated valuation and traded end of year “pockets” for bonus elevation, as well as alternating sentiment leaving the sector vulnerable to bad news and perhaps simply in need of a breather.

  • Never forget end of year tax selling and portfolio rotation due to recommendations
  • From oversold to outperform, in recent sessions we need to see the cell and gene therapy sector run a bit hotter.

Get your blinders’ off … November’s 17th session … 8 positive and 9 negative closes earnings’ close out the season.

 

Ranking the end of October:      

  • 11/25 - Monday closed positive with 28 incliner, 6 decliners and 1 flat
  • 11/22 - Friday closed positive with 25 incliner, 9 decliners and 1 flat
  • 11/21 – Thursday: closed positive with 18 incliner, 16 decliners and 1 flat
  • 11/20 – Wednesday: closed negative with 15 incliner, 17 decliners and 3 flats
  • 11/19 – Tuesday closed positive with 19 incliner, 14 decliners and 2 flats
  • 11/18 – Monday closed negative with 14 incliner, 20 decliners and 1 flat

 

Portfolio managers are addressing rotations as year comes to years-end.

  • I keep writing about uncertainty and skepticism … and coming realities.
  • Even with the potential for some market hiccups along the way, the good news is Q4 has historically skewed positively, even as sector earnings kicked the bucket down the road!

 

The top three (3) performing in the session:    

  • Monday: Alnylam Pharmaceuticals (ALNY), Moderna (MRNA) and CRISPR Therapeutics (CRSP)
  •  
  • Friday: Moderna (MRNA), Vericel (VCEL) and CRISPR Therapeutics (CRSP)

The worst three (3) in the session: 

  • Monday: Vericel (VCEL), Blueprint Medicine (BPMC) and Ultragenyx Pharmaceuticals (RARE)
  •  
  • Friday: Blueprint Medicine (BPMC), Alnylam Pharmaceuticals (ALNY) and Harvard Apparatus RT (OTCQB: HRGN)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.